On June 30, 2022, the FDA and FTC jointly issued warning letters to four companies, including Omni Consumer Products LLC, doing business as YoKratom, regarding the unapproved marketing of kratom products. The letters emphasized that kratom is not authorized for treating opioid use disorder or withdrawal symptoms and highlighted significant safety concerns raised by the FDA. The investigation revealed that these companies were making misleading health claims about kratom’s effectiveness for pain relief, depression, and blood pressure management. The FDA advised consumers against using kratom for medical purposes, underscoring the need for regulatory scrutiny in the kratom marke
Menu
